Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals, Inc. develops and commercializes therapies for rare hematology diseases, centered on mavorixafor, an oral CXCR4 antagonist marketed in the U.S. as XOLREMDI® in its first indication. Company news covers regulatory and commercial updates for XOLREMDI, including European authorization for WHIM syndrome and the Norgine license and supply relationship for selected ex-U.S. territories.
Recurring updates also address the 4WARD Phase 3 program evaluating mavorixafor in chronic neutropenia, quarterly financial results, product revenue, research and development spending, cash resources, restructuring effects, conference participation, and equity inducement grants under Nasdaq listing rules.
X4 Pharmaceuticals (Nasdaq: XFOR) announced the EMA CHMP has issued a positive opinion recommending marketing authorization under exceptional circumstances for mavorixafor (XOLREMDI) to treat WHIM syndrome in the EU. The European Commission is expected to issue a final decision in Q2 2026.
CHMP support is based on the Phase 3 4WHIM trial showing statistically significant increases in ANC and ALC thresholds, ~40% reduction in total infection score, and a 60% reduction in annualized infection rate versus placebo. X4 has a commercialization license with Norgine and may receive up to €226 million plus escalating royalties.
X4 Pharmaceuticals (Nasdaq: XFOR) announced management will participate in the Guggenheim Emerging Outlook: Biotech Summit on February 11–12, 2026 in New York.
The company will hold a fireside chat on February 12 at 12:30 p.m. ET, offer one-on-one investor meetings, and provide a webcast and 30-day replay on its Investors Events and Presentations page.
X4 Pharmaceuticals (Nasdaq: XFOR) issued inducement option awards effective January 30, 2026, under its 2019 Inducement Equity Incentive Plan to new employees.
The awards total 20,000 options, each with a ten‑year term and an exercise price of $3.70 (closing price on January 30, 2026). Options vest over four years (25% after 12 months, then monthly over 36 months).
X4 Pharmaceuticals (Nasdaq: XFOR) announced that its management team will participate in the Guggenheim Second Annual Healthcare Innovation Conference in Boston on November 10–12, 2025. The company will host a fireside chat on November 10 at 8:30 a.m. ET and will be available for one-on-one investor meetings. A live webcast of the fireside chat will be available on the company’s Investors > Events and Presentations page, with a replay accessible for 30 days after the event. For more information, visit investors.x4pharma.com.
X4 Pharmaceuticals (Nasdaq: XFOR) reported Q3 2025 results and a corporate update focused on advancing the 4WARD Phase 3 trial of mavorixafor for chronic neutropenia. The company completed two financings totaling $240.3M and said cash runway now extends to the end of 2028, supporting trial completion, a potential sNDA filing and a possible 2028 launch if successful. Operational changes include a 50% workforce reduction (estimated $13M annualized savings), deprioritization of WHIM commercialization, promotion of John Volpone to COO, and an increased 4WARD enrollment target of 176 patients with completion expected in Q3 2026.
Q3 net product sales were $1.6M, Q3 net loss was $29.8M (EPS -$0.69), and cash, cash equivalents and short-term investments were $122.2M as of Sept 30, 2025.
X4 Pharmaceuticals (Nasdaq: XFOR) closed an underwritten public offering on October 27, 2025, selling 52,844,000 common shares including the full exercise of a 6,984,000-share underwriter option at $2.90 per share.
The company also issued pre-funded warrants for up to 700,000 shares at a public price of $2.899 each, exercisable immediately at $0.001 per share. Aggregate gross proceeds were approximately $155.3 million before underwriting discounts, commissions and offering expenses. Total shares outstanding after the offering were 79,214,708. Joint bookrunners were Leerink Partners, Stifel and Guggenheim Securities.
X4 Pharmaceuticals (Nasdaq: XFOR) priced an underwritten public offering of 45,860,000 shares at $2.90 per share and up to 700,000 pre-funded warrants at $2.899 each (exercise price $0.001). The offering is expected to generate approximately $135 million in gross proceeds before underwriting discounts, commissions and expenses and is expected to close on October 27, 2025, subject to customary conditions.
X4 granted underwriters a 30-day option to buy up to an additional 6,984,000 shares. Net proceeds will fund the pivotal Phase 3 development of mavorixafor in certain chronic neutropenic disorders and support general corporate purposes.
X4 Pharmaceuticals (Nasdaq: XFOR) commenced an underwritten public offering on October 23, 2025 of shares of common stock or, for certain investors, pre-funded warrants to purchase common stock. The company expects to grant underwriters a 30-day option to buy up to an additional 15% of the offered securities. The offering is subject to market and other conditions and may not be completed.
Use of proceeds is stated as funding the pivotal Phase 3 development of mavorixafor in certain chronic neutropenic disorders, plus general and administrative expenses, capital expenditures, working capital and other corporate purposes. Leerink Partners, Stifel and Guggenheim are joint bookrunning managers. A shelf registration became effective on August 24, 2023.
X4 Pharmaceuticals (NASDAQ:XFOR) announced a major strategic restructuring aimed at streamlining operations and focusing on its 4WARD Phase 3 trial in chronic neutropenia patients. The restructuring includes a 50% workforce reduction, expected to generate $13 million in annual cost savings.
Key management changes include John Volpone's appointment as COO while retaining his President role, and Dr. Adam Craig (Executive Chairman) taking oversight of clinical development. Several executives, including the Chief Legal Officer, former COO, Chief Commercial Officer, and Chief Medical Officer, will be departing the company.
[ "Expected annual cost savings of $13 million from restructuring", "Streamlined management structure with focused leadership", "Strategic focus on advancing 4WARD Phase 3 trial in chronic neutropenia" ]X4 Pharmaceuticals (Nasdaq: XFOR) has announced significant inducement grants to three new executive officers under its 2019 Inducement Plan. The grants include stock options for 12.7 million shares issued on August 12, 2025, and additional 1.4 million shares on August 14, 2025.
The initial grants were distributed among Dr. Adam Craig, John Volpone (4.25 million shares each), and David Kirske (2.83 million shares) at $1.42 per share. Additional grants were issued at $3.14 per share following X4's $85 million private placement. The options feature varying vesting schedules over 18-36 months, subject to performance conditions and continued employment.